ClinicalTrials.gg
RecruitingNCT07502820POWERUpdated Aug 12, 2026

The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER

A Phase 3 interventional study of Individual dose of tamoxifen and Standard adjuvant therapy of tamoxifen in Breast Cancer and Adjuvant Drug Therapy, sponsored by Karolinska Institutet. Recruiting at 4 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Karolinska Institutet · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.

Planned enrollment
4th of 18
1,100 · median 175
Started
2026
with 1 other
Phase 3
3 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 3, and was the 19th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Karolinska Institutet, or all of them as a file.
02

Study summary

In Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years to improve prognosis. Tamoxifen, one of the most widely used anti-hormonal agents globally, reduces the risk of recurrence by 40% and breast cancer mortality by 30%.

Tamoxifen is a pro-drug that undergoes hepatic metabolism to form endoxifen and other active metabolites. Variability in metabolic capacity affects therapeutic efficacy: poor metabolisers produce insufficient endoxifen and other active metabolites, risking therapeutic failure, while ultrarapid metabolisers generate excessive amounts, leading to intolerable adverse effects. Today, 30-50% of patients discontinue treatment prematurely due to severe side effects, resulting in suboptimal outcomes.

Currently, tamoxifen is uniformly prescribed at a daily dose of 20 mg, and so far, no clinical trials have tested whether individualised dosing could enhance adherence and improve survival outcomes. The primary objective is to evaluate whether individualised tamoxifen dosing reduces discontinuation rates and enhances patient outcomes in breast cancer treatment.

03

Conditions studied

  • Breast Cancer
  • Adjuvant Drug Therapy

Browse trials for

Keywords

  • Early-stage breast cancer
  • Adjuvant
  • Endocrine therapy
  • Tamoxifen
  • Therapeutic drug monitoring TDM
  • Precision medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primary breast cancer, recommended for tamoxifen treatment with or without concomitant goserelin
  • Premenopausal or perimenopausal, defined according to SOC for therapy decision
  • (ECOG) WHO Performance Scale 0 - 2
  • Participants must use non-hormonal during the trial.

Exclusion criteria

Exclusion Criteria:

  • Previous use of tamoxifen, endoxifen, or aromatase inhibitors.
  • Previous medical history of:

Deep venous thrombosis or pulmonary embolism; bleeding disorder or coagulopathy; macular disorders, retinal disorders, severe cataract or glaucoma.

  • Current use of warfarin.
  • Not willing to abstain from strong and moderate CYP2D6 inhibitors or inducers during the tamoxifen treatment
  • Current pregnancy, breastfeeding, or already at start of tamoxifen planning to become pregnant within the next two years
  • Use of systemic menopausal hormonal therapy (MHT).
  • Prior invasive during the last five years. Prior or current in situ cancers are allowed.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    Individualised care with tamoxifen dose adjustments.

    Patients randomised to individualised care will have their dose adjusted according to an algorithm based on patient reported side effects and the concentration of (z)-endoxifen in blood.

    Drug: Individual dose of tamoxifen

  • Active comparator
    Standard-of-care with the standard tamoxifen dose of 20 mg orally once per day.

    In the control arm, each subject undergoes treatment with the standard dose 20 mg tamoxifen daily by oral intake of one tablet, with no possibilty of dose adjustment during the trial.

    Drug: Standard adjuvant therapy of tamoxifen

Interventions

  • DrugIndividual dose of tamoxifen

    Each subject starts their treatment with the standard dose 20 mg tamoxifen daily by oral intake. During visits 2 (3 months), 3 (six months) and 4 (twelve months), the investigator will either let the patient remain on 20 mg tamoxifen or individualise the dose. The investigator may change the daily tamoxifen from 20 mg per day to: a halved dose to 10 mg, or a doubled dose to 40 mg. The recommendation for oral intake of tablet(s) tamoxifen for a daily dose of 10, 20 or 40 mg is accordingly: for 10 mg: one tablet (20 mg) every two days for 20 mg: one tablet (20 mg) every day for 40 mg: two tablets (20 mg) every day.

  • DrugStandard adjuvant therapy of tamoxifen

    The global standard dose for everyone is 20 mg orally once per day. Each subject undergoes treatment with the standard dose 20 mg daily by oral intake of one tablet, with no possibility of dose adjustment during the trial.

06

What researchers measure

Primary outcomes

  1. Discontinuation of tamoxifen.

    The primary outcome is discontinuation of tamoxifen. This will be declared when any of the following four criteria are satisfied: * Agreement between patient and doctor that the patient will discontinue tamoxifen. * Patient notifies doctor that she has discontinued tamoxifen. * Patient-reported tamoxifen tablet intake of zero tablets for 13 consecutive weeks. * Patient refuses dose of tamoxifen as recommended per protocol by their clinician.

    Time frame: From enrollment to end of treatment at 60 months.

Secondary outcomes

  1. Patient reported outcomes.

    At baseline and two weeks before the doctor's appointment at 3, 6 and 12 months after start of tamoxifen therapy all patients will answer the POWER symptom burden questionnaire. Patients will be answering questionnaires yearly year 2-5 from start of tamoxifen. The purpose is evaluate treatment-related side effects (e.g., tamoxifen). The symptom burden questionnaire includes the BCPT Eight Symptom Scale (BESS) (derived from the 42-item Breast Cancer Prevention Trial checklist), which is a 30-item, 5-point Likert-type, self-report tool measuring symptom distress in breast cancer patients over the past four weeks. It covers eight specific domains (hot flashes, nausea, bladder/vaginal problems, pain, cognitive, weight, arm problems). Higher scores indicate higher symptom distress, where patients rate how "bothered" they were on a scale of 0 (Not at all) to 4 (Extremely).

    Time frame: From enrollment to end of treatment at 60 months.

  2. Quality of life questionnaire

    At baseline and two weeks before the doctor's appointment at 3, 6 and 12 months after start of tamoxifen therapy all patients will answer the quality-of-life questionnaire designed for this study. A prespecified set of answers from the questionnaire will be available for the doctor and patient to discuss at the appointment. Patient will be answering the same questionnaire yearly year 2-5 in the study. The results from the questionnaires will not be discussed with the patient but analysed at the end of the study.

    Time frame: From enrollment to end of treatment at 60 months.

  3. Concentration of circulation plasma metabolites

    Tamoxifen and the metabolites 4-OH-tamoxifen, N-DM-tamoxifen, and endoxifen will be analysed in plasma at each blood collection time point. For patients in the intervention arm, the endoxifen concentration will be accessible in the patient eCRF and discussed at the doctor's visit for decision on the appropriate dose. For patients in the control arm, neither the patient nor the doctor will have access to the endoxifen concentrations during the trial. Endoxifen concentrations in the control arm will remain pseudonymised and stored on servers without access for investigators or relevant study personnel until end-of-trial.

    Time frame: From 3 months after treatment start to end of treatment at 60 months

  4. Invasive disease-free survival (iDSF)

    iDSF measures the time from randomized treatment or surgery until the first occurrence of an invasive cancer recurrence, a new primary invasive cancer, or death from any cause. Study site will report first recurrence, local or distant during the patients 5 years in the study. For long-term follow-up the information about first recurrence or death will be collected from the National Cancer Registry.

    Time frame: From enrollment to end of treatment at 60 months.

  5. Distant relapse-free survival (DRFS)

    DRFS measures the time from primary cancer treatment until the first recurrence at a distant site (metastasis) or death from the cancer, excluding local-regional recurrences. Site will report first recurrence during the patients 5 years in the study. For long-term follow-up the information about first recurrence or death will be collected from the National Cancer Registry.

    Time frame: From enrollment to end of treatment at 60 months.

  6. Breast cancer specific survival (BCSS)

    BCSS is the percentage of people with a specific type and stage of breast cancer who are alive at a certain time (often 5 or 10 years) following diagnosis, accounting only for deaths caused by that cancer. Unlike overall survival, BCSS excludes deaths from other causes. The site will report during the patients 5 years in the study. For long-term follow-up, the information about death will be collected from the National Cancer Registry.

    Time frame: From enrollment to end of treatment at 60 months.

  7. Overall survival (OS)

    The study site will report death during the first 5 years in the study. For long-term follow-up the information about death will be collected from the National Cause-of-Death registry.

    Time frame: From enrollment to end of treatment at 60 months.

  8. Mammographic breast density

    Assess change in mammographic density including time-and dose-dependent trends in density change. The mammograms will be collected for a centralised assessment of density and density change. An automated, digital software, e.g. the Stratus software, will be used to measure mammographic features such as density, macrocalcifications and masses.

    Time frame: From enrollment to end of treatment at 60 months.

  9. Cost effectiveness Analysis (CEA)

    CEA will be used to compare relative costs and effects of the intervention, expressed as Quality-Adjusted Life Years (QUALYs) gained. Cost effectiveness and values of the intervention i.e. individualised adjuvant tamoxifen will be evaluated using the POWER trial questionnaires, medical records, National Register information, number and extents of health care contacts, and concomitant medications, collected through the trial.

    Time frame: From enrollment to end of treatment at 60 months.

  10. Cost-Benefit Analysis (CBA)

    CBA will be used to investigate any monetary value of individualised tamoxifen, measured by impacts on all direct and indirect costs. Values of the intervention i.e. individualised adjuvant tamoxifen will be evaluated using the POWER trial questionnaires, medical records, National Register information, number and extent of health care contacts. and concomitant medications, collected through the trial.

    Time frame: From enrollment to end of treatment at 60 months.

  11. Incremental cost-effectiveness ratio (ICER)

    ICER will be calculated by dividing the incremental cost of the intervention i.e. individualised adjuvant tamoxifen by its incremental health benefit. Cost effectiveness and values of the intervention will be evaluated using the POWER trial questionnaires, medical records, National Register information, number and extents of health care contacts, and concomitant medications, collected through the trial.

    Time frame: From enrollment to end of treatment at 60 months.

Other outcomes

  1. Number of participants with genetic polymorphisms in germline DNA

    Measure genetic polymorphism in germline DNA and relate it to the primary endpoint and other secondary and exploratory endpoits, e.g. discontinuation, (z)-endoxifen concentrations, and side effects. It will be explored if, and to what extent, genetic polymorphism in germline DNA is contributing information that could be used in the interpretation of the primary and secondary findings.

    Time frame: Blood collection at enrollment

  2. Number of biomarkers of potential use for therapeutic drug monitoring

    Exploratory analysis will be done after the primary analysis, in plasma collected at baseline and follow-up blood drawls, and stored at the Karolinska Institutet Biobank. Exploratory analysis will be used to identify biomarkers of potential use for therapy effect, dose-response, side effects and tolerability, and heterogeneity of drug response. Exploratory analyses will also be used for deconvolute dominant phenotypes and markers and predictors of heterogeneity. Exploratory analyses will, among others, include endogenous hormones, proteomics, metabolomics, lipidomics, extracellular vesicles, ctDNA, cfDNA, miRNA and siRNA.

    Time frame: From enrollment to end of treatment at 60 months.

07

Study locations

2 of 4 sites recruiting
  • S:a Älvsborgs Sjukhus
    Borås, 501 82, Sweden
    Not yet recruiting
    • Rebecka Landin, MD PhD · Principal investigator
  • Skaraborgs Sjukhus
    Skövde, 549 49, Sweden
    Recruiting
    • Chaido Chamalidou, MD PhD · Principal investigator
  • Capio S:t Görans Sjukhus
    Stockholm, 112 81, Sweden
    Not yet recruiting
    • Jenny Bergqvist, MD PhD · Principal investigator
  • Södersjukhuset, Onkologiska kliniken
    Stockholm, 118 61, Sweden
    Recruiting
    • Linda Thorén, MD PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2036, 124 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 124 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 31, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Aug 2036
CompletionEst.
Aug 2036
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502820
Collaborators
Swedish Cancer Society, Region Stockholm, The Swedish Breast Cancer Association, The Sjöberg Foundation, The Cancer Research Foundations of Radiumhemmet
Responsible party
Marike Gabrielson (Sponsor representative and Chief Scientific Scientific Officer, Karolinska Institutet) — Principal investigator
First posted
Mar 31, 2026
Start date
Apr 14, 2026
Primary completion
Aug 2036 (estimated)
Completion
Aug 2036 (estimated)
Last update
Aug 12, 2026

Study contacts

Helena Aaröe, RN
Contact
powerstudien-meb@ki.se
+46852482267
Marike Gabrielson, PhD
principal investigator · Karolinska Institutet
Jenny Bergkvist, MD, PhD
study chair · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion